Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.

Posted on by

CONCLUSIONS: Evaluating prescription opioid-dependent patients after 2 weeks of buprenorphine-naloxone treatment may help determine the likelihood of successful outcome at completion of the current treatment regimen.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00316277.
PMID: 25562462 [PubMed – as supplied by publisher] (Source: Journal of Clinical Psychiatry)